Phase I Study of 506U78 Administered on a Consecutive 5-Day Schedule in Children and Adults With Refractory Hematologic Malignancies

Abstract

Nelarabine is a novel nucleoside with significant cytotoxic activity against malignant T cells. DLT is neurologic. Phase II and III trials in patients with T-cell malignancies are encouraged.

Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T‐cell lymphoblastic leukaemia and lymphoma

“…The early phase trials with AraG have been very promising, although neurotoxicity must be closely monitored (Berg et al, 2005;Kurtzberg et al, 2005;Cohen et al, 2008;DeAngelo, 2009). The Children's Oncology Group and the Cancer Research United Kingdom collaborative are actively studying the efficacy of AraG in a randomized fashion in combination with standard ALL chemotherapy in newly diagnosed paediatric patients with T-cell ALL.…”

“…A third of patients had peripheral sensory and/or motor neuropathy, but only rarely at grade 3 or higher. Other toxicities included haematological, fatigue, musculoskeletal weakness or pain, and nausea/vomiting (Berg et al, 2005;Kurtzberg et al, 2005;Cohen et al, 2008;DeAngelo, 2009).The combination of etoposide (VP) and cyclophosphamide (CPM) is used widely for refractory and relapsed lympho- (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma. The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain.…”

“…A third of patients had peripheral sensory and/or motor neuropathy, but only rarely at grade 3 or higher. Other toxicities included haematological, fatigue, musculoskeletal weakness or pain, and nausea/vomiting (Berg et al, 2005;Kurtzberg et al, 2005;Cohen et al, 2008;DeAngelo, 2009).…”

Sequential chemotherapy and myeloablative allogeneic hematopoietic stem cell transplantation for refractory acute lymphoblastic leukemia

“…Some clinical studies have been conducted in patients with relapsed or refractory ALL to assess the safety and efficacy of novel anti-leukemic agents, including nucleotide analogs [16][17][18] and molecular targeted agents [19,20]. While these agents were tolerable, responses were not completely satisfactory.…”

Clinical Characteristics and Treatment Results of Pediatric Relapsed/Refractory Non-Hodgkin’s Lymphomas

“…Следует отметить, что результаты лечения не зависели от варианта ТГСК и были одинаковыми при алло-и аутоТГСК [24]. В другом исследовании было показано, что несмотря на одинаковые показатели ОВ при проведении аллоТГСК и аутоТГСК (36 и 39 % соответственно) частота повторных рецидивов ЛБЛ при проведении аллоТГСК существенно ниже [25][26][27]. Данный факт, вероятно, объясняется эффектом «трансплантат про-тив опухоли», который реализуется в случаях алло-ТГСК.…”